Celgene Corporation Reviews 2004 Achievements and Announces 2005 Financial Outlook
Celgene Corporation today reviewed its clinical and commercial progress in 2004 and provided its initial outlook for 2005 at the J.P. Morgan 23rd Annual Healthcare Conference.
In 2004, Celgene achieved outstanding results in its commercial operations, financial performance, and clinical performance advancing REVLIMID(R) in key clinical trials.
The growing success of the Company's commercial franchise was demonstrated by the continued acceleration of product revenue and profit growth that reflects the positive impact of new clinical data on Celgene products presented at major international medical meetings such as American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH), as well as an expanding volume of multiple peer-reviewed articles in major publications such as The Journal of Clinical Oncology and The New England Journal of Medicine.
Celgene intends to disseminate its 2004 full-year financial results on January 27, 2005.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.